The Treatment of Pulmonary Tuberculosis
- 1 December 1979
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 139 (12) , 1391-1395
- https://doi.org/10.1001/archinte.1979.03630490047016
Abstract
Appropriate chemotherapy must be received by the patient if the treatment of pulmonary tuberculosis is to be successful. The choice of the antituberculous regimen depends on the susceptibility and number of organisms infecting the patient and the side effects and cost of the drugs. The patient's life-style and the resources available in the community need to be considered to ensure compliance with the prescribed chemotherapy. If treatment is to be unsupervised, meaning that each dose is not actually witnessed by a health provider, a daily isoniazid and ethambutol hydrochloride treatment for 18 months or daily isoniazid and rifampin treatment for nine months is suggested. If each dose of chemotherapy is to be directly supervised, necessary for the noncompliant patient, then the following regimens are recommended: intermittent isoniazid and ethambutol, isoniazid and streptomycin, or intermittent isoniazid and rifampin following an initial period of daily therapy. (Arch Intern Med 139:1391-1395, 1979)This publication has 8 references indexed in Scilit:
- Long-term effectiveness of intermittent therapy for tuberculosis: final report of three Denver studies.Published by Elsevier ,1980
- The current status of short-course chemotherapyTubercle, 1979
- Short-course Chemotherapy for Tuberculosis with Largely Twice-weekly Isoniazid-RifampinChest, 1979
- Short-Course Chemotherapy in Pulmonary TuberculosisPublished by Springer Nature ,1976
- Ethambutol-isoniazid versus streptomycin-ethambutol-isoniazid in original treatment of cavitary tuberculosis.Published by Elsevier ,1974
- Infectivity of sputum-positive tuberculous patients on chemotherapy.Published by Elsevier ,1974
- Routine follow-up of inactive tuberculosis: a practice that has been abandoned.Published by Elsevier ,1973
- In vivo and in vitro Suppression of Humoral and Cellular Immunological Response by RifampicinNature, 1970